Blocking Cannabis Receptor Reduced Weight and Improved Asthma in Obese Mice
A CB1 receptor inverse agonist caused significant weight loss and improved airway function in obese asthmatic mice, partly through effects on lung surfactant.
Quick Facts
What This Study Found
The CB1R inverse agonist INV-202 produced 11% weight loss in lean and 27% in obese mice. Both groups showed improved airway hyperresponsiveness, particularly reduced lung elastance. The drug also reduced inflammation markers and increased beneficial surfactant lipids in lung fluid.
Key Numbers
Weight loss: 11% (lean) and 27% (obese). 33% decrease in CCL20 in lean mice. 55% decrease in airway neutrophils. Increased phosphatidylglycerol correlated with improved lung compliance.
How They Did This
Mouse model combining high-fat diet obesity and house dust mite allergic airway inflammation, with oral CB1R inverse agonist treatment and comprehensive lung function, inflammation, and lipid analysis.
Why This Research Matters
Obesity is the strongest risk factor for severe asthma, and the two conditions likely share metabolic pathways. This study identifies the endocannabinoid system as a treatable link between obesity and asthma.
The Bigger Picture
Most asthma treatments target airway inflammation directly. This approach targets the metabolic dysfunction underlying obese asthma, potentially addressing root causes rather than just symptoms.
What This Study Doesn't Tell Us
Mouse obesity and asthma models may not fully replicate human disease. First-generation CB1R antagonists (rimonabant) were withdrawn due to psychiatric side effects. Long-term safety of INV-202 not established.
Questions This Raises
- ?Does INV-202 avoid the psychiatric side effects that doomed rimonabant?
- ?Would weight loss alone explain the lung improvements, or is CB1R inhibition directly beneficial for airways?
Trust & Context
- Key Stat:
- 27% weight loss and improved airway function from blocking CB1 receptor in obese mice
- Evidence Grade:
- Well-designed preclinical study with comprehensive outcomes, but mouse models have significant translational limitations.
- Study Age:
- 2025 animal study with a novel CB1R inverse agonist approach.
- Original Title:
- A cannabinoid receptor 1 inverse agonist induces weight loss and reduces airway hyperresponsiveness in a mouse model of obese asthma.
- Published In:
- American journal of physiology. Lung cellular and molecular physiology, 329(3), L327-L340 (2025)
- Authors:
- Morris, Carolyn R, Chandrasekaran, Ravishankar, Butzirus, Isabella M, Daphtary, Nirav, Aliyeva, Minara, Manuel, Allison M, Tharp, William G, Bates, Jason H T, Anathy, Vikas, Poynter, Matthew E, Duan, Jianmin, Gaucher, Geneviève, Crater, Glenn D, Dixon, Anne E
- Database ID:
- RTHC-07191
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
Could blocking cannabis receptors help with asthma?
In obese mice, blocking the CB1 cannabinoid receptor caused weight loss and improved airway function. This suggests the endocannabinoid system connects obesity and asthma, offering a potential new treatment target.
Is this related to rimonabant?
Similar concept but different compound. Rimonabant, an earlier CB1 blocker for weight loss, was withdrawn due to psychiatric side effects. INV-202 is a newer inverse agonist, but its safety profile in humans is not yet known.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-07191APA
Morris, Carolyn R; Chandrasekaran, Ravishankar; Butzirus, Isabella M; Daphtary, Nirav; Aliyeva, Minara; Manuel, Allison M; Tharp, William G; Bates, Jason H T; Anathy, Vikas; Poynter, Matthew E; Duan, Jianmin; Gaucher, Geneviève; Crater, Glenn D; Dixon, Anne E. (2025). A cannabinoid receptor 1 inverse agonist induces weight loss and reduces airway hyperresponsiveness in a mouse model of obese asthma.. American journal of physiology. Lung cellular and molecular physiology, 329(3), L327-L340. https://doi.org/10.1152/ajplung.00049.2025
MLA
Morris, Carolyn R, et al. "A cannabinoid receptor 1 inverse agonist induces weight loss and reduces airway hyperresponsiveness in a mouse model of obese asthma.." American journal of physiology. Lung cellular and molecular physiology, 2025. https://doi.org/10.1152/ajplung.00049.2025
RethinkTHC
RethinkTHC Research Database. "A cannabinoid receptor 1 inverse agonist induces weight loss..." RTHC-07191. Retrieved from https://rethinkthc.com/research/morris-2025-a-cannabinoid-receptor-1
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.